Related coverage linked through entity extraction aliases.
May 02, 2026
The Fifth Circuit reinstated an in-person dispensing requirement for mifepristone, blocking telemedicine prescriptions. The ruling came after a federal judge paused Louisiana's lawsuit pending the FDA's safety review of the abortion medication.
Apr 24, 2026
A federal appeals court affirmed a ruling finding no infringement of two Korlym-related patents by Teva's proposed generic. The decision removes a major legal barrier for generic competition.
Mar 20, 2026
The FDA announced major policy changes including requiring only one study for drug approvals instead of two, and offering performance bonuses to reviewers who complete work ahead of schedule while maintaining thoroughness.
Mar 14, 2026
Sen. Josh Hawley and Rep. Diana Harshbarger introduced legislation to withdraw FDA approval of mifepristone nationwide, making distribution a federal violation and allowing patients to sue manufacturers.
Mar 14, 2026
The Trump administration launched TrumpRx on Feb. 5, a prescription drug website that displays discounted prices on 43 brand-name medications for out-of-pocket purchasers without insurance coverage.
Mar 01, 2026
Corcept Therapeutics received an FDA Complete Response Letter denying approval of relacorilant for hypertension secondary to hypercortisolism, triggering a 44.76% stock decline and multiple securities class actions.
Feb 18, 2026
Twenty-one state attorneys general and 60 members of Congress filed amicus briefs supporting Louisiana's lawsuit challenging the FDA's 2023 policy that removed in-person dispensing requirements for mifepristone, enabling mail-order distribution of abortion drugs.
Feb 18, 2026
59 Republican senators filed an amicus brief supporting Louisiana's lawsuit against the FDA, arguing the agency violated federal law by removing in-person dispensing requirements for mifepristone.
Feb 20, 2026
The U.S. Court of Appeals for the Federal Circuit ruled that Teva Pharmaceuticals did not infringe Corcept Therapeutics' patents for methods of safely co-administering Korlym with CYP3A4 inhibitors, affirming a 2023 district court verdict.
Feb 14, 2026
Sixty Republican members of Congress filed an amicus brief supporting Louisiana's lawsuit to restore in-person dispensing requirements for mifepristone, challenging Biden-era rules allowing mail-order abortion drugs.
Sep 11, 2025
The FDA issued a Complete Response Letter for Corcept's relacorilant as a treatment for hypertension secondary to hypercortisolism, requesting additional evidence of effectiveness despite acknowledging positive trial results.
